Ledikast 400mg Tablet (ledipasvir + sofosbuvir)

Ledikast 400mg Tablet (ledipasvir + sofosbuvir) is an antiviral medication that is used to treat chronic Hepatitis C virus infection. It contains sofosbuvir and ledipasvir as the active ingredient that belongs to the class of medications known as direct-acting antiviral medications. It works by blocking an enzyme called NS5B polymerase, which helps the hepatitis C virus to multiply. As a result, it reduces viral load in the body, reduces viral inflammation, and controls virus progression as well as ultimately eradicating virus traces in the body. Ledikast 400mg Tablet (ledipasvir + sofosbuvir) is generally used as part of a combination antiviral treatment.

The tablet is taken orally and exactly as prescribed by the doctor. The tablet must be swallowed whole with water and should not be crushed, chewed, or broken. It is usually taken with or without food. Ledikast 400mg Tablet (ledipasvir + sofosbuvir) is given once daily, and a doctor decides the dose and timings according to the patient's condition, combination therapy, clinical response, and stage of liver disease. Patients are advised not to change the dosage because it can lead to severe side effects.

Common side effects include headache, tiredness, nausea, difficulty sleeping, and weakness. A few patients can undergo severe side effects, including severe allergic reactions, significant heart rate slowing, and reactivation of hepatitis B. Most of the Ledikast 400mg Tablet (ledipasvir + sofosbuvir) side effects tend to resolve when the body adapts to the medicine. However, if any side effects persist, inform your doctor immediately.

Inform your doctor about any history of hepatitis B, liver disease, HIV infection, or liver transplantation before the treatment. The medicine can cause serious harm to an unborn baby, and pregnant women must avoid using it. Patients must list all medicines, supplements, and herbal products that they are taking. The Ledikast 400mg Tablet (ledipasvir + sofosbuvir) must be used under medical oversight or medical supervision only. Attend regular tests and follow-ups to monitor the medicine response and reduce side effects. Before making any adjustments, changing the dose, or stopping the treatment, consult with your doctor to maximize the benefit.

Chronic Hepatitis C virus infection

Ledikast 400mg Tablet (Ledipasvir and Sofosbuvir) may cause side effects ranging from mild to serious. Patients should seek immediate medical attention if they experience severe or worsening symptoms, especially the rare ones.

Common Side Effects of Ledikast 400mg Tablet
● Headache
● Nausea
● Weakness
● Diarrhea
● Muscle Pain
● Joint Pain
● Irritability
● Insomnia
● Cough
● Loss of Appetite
● Feeling Sad
● Abdominal Pain

Rare but Serious Side Effects of Ledikast 400mg Tablet
● Severe Allergic Reaction
● Shortness of Breath
● Jaundice
​● Dark urine
● Chest Pain
● Irregular Heartbeat
● Severe abdominal pain
● Signs of Hepatitis B Reactivation (in patients co-infected with HBV)

The Ledikast 400mg Tablet (ledipasvir and sofosbuvir) needs to be swallowed whole. Avoid chewing, breaking, biting and crushing the tablet, as it may affect its efficacy. Dosage may vary based on the treatment stage as well as the patient's overall health. Consult your doctor for personalized dosage and guidance.

● Naggie, S., Cooper, C., Saag, M., Workowski, K., Ruane, P., Towner, W. J., ... & Sulkowski, M. (2015). Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. New England Journal of Medicine, 373(8), 705-713.
● Keating, G. M. (2015). Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C. Drugs, 75(6), 675-685.
● German, P., Mathias, A., Brainard, D. M., & Kearney, B. P. (2018). Drug–drug interaction profile of the fixed-dose combination tablet regimen ledipasvir/sofosbuvir. Clinical pharmacokinetics, 57(11), 1369-1383.
● Abdelaty, L. N., Elnaggar, A. A., Said, A. A., & Hussein, R. R. (2020). Ledipasvir/sofosbuvir versus daclatasvir/sofosbuvir for the treatment of chronic hepatitis C genotype 4 patients. Current Drug Safety, 15(1), 53-60.